{"protocolSection":{"identificationModule":{"nctId":"NCT01059643","orgStudyIdInfo":{"id":"12848"},"secondaryIdInfos":[{"id":"I1Y-MC-JFBF","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck","officialTitle":"A Phase 2 Indication Identification Study of LY2523355 in Patients With Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck"},"statusModule":{"statusVerifiedDate":"2019-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-04"},"primaryCompletionDateStruct":{"date":"2012-12","type":"ACTUAL"},"completionDateStruct":{"date":"2012-12","type":"ACTUAL"},"studyFirstSubmitDate":"2010-01-11","studyFirstSubmitQcDate":"2010-01-29","studyFirstPostDateStruct":{"date":"2010-02-01","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-09-27","resultsFirstSubmitQcDate":"2017-10-28","resultsFirstPostDateStruct":{"date":"2017-12-04","type":"ACTUAL"},"dispFirstSubmitDate":"2013-04-30","dispFirstSubmitQcDate":"2013-04-30","dispFirstPostDateStruct":{"date":"2013-05-08","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-09-09","lastUpdatePostDateStruct":{"date":"2019-09-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355."},"conditionsModule":{"conditions":["Ovarian Cancer","Non Small Cell Lung Cancer","Prostate Cancer","Colorectal Cancer","Gastric Cancer","Esophageal Cancer","Cancer of Head and Neck"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":103,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"LY2523355","type":"EXPERIMENTAL","interventionNames":["Drug: LY2523355","Drug: pegfilgrastim"]}],"interventions":[{"type":"DRUG","name":"LY2523355","description":"Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.","armGroupLabels":["LY2523355"]},{"type":"DRUG","name":"pegfilgrastim","description":"6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.","armGroupLabels":["LY2523355"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With a Complete Response (CR) or Partial Response (PR)","description":"The percentage of participants who achieved a best response of either CR or PR, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm) and normalization of tumor marker level of non-target lesions. PR was defined as at least a 30% decrease in sum of longest diameter of target lesions and for prostate cancer PR was defined as a ≥50% decrease in baseline prostate-specific antigen (PSA) value that was confirmed with a second value ≥3 weeks later. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase over nadir. Percentage is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.","timeFrame":"Baseline until progressive disease up to 36 weeks post-baseline"}],"secondaryOutcomes":[{"measure":"Progression Free Survival (PFS)","description":"PFS defined as the time from date of first dose to the first observation of disease progression or death due to any cause. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 millimeter (mm) increase over nadir. For participants who were not known to have died or to have progressed as of the data inclusion cutoff date, PFS were censored at the date of the last objective progression-free disease assessment prior to the date of any subsequent systemic anticancer therapy.","timeFrame":"Date of enrollment to progressive disease or death due to any cause up to 36 weeks post-enrollment"},{"measure":"Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm) and normalization of tumor marker level of non-target lesions. PR was defined as at least a 30% decrease in sum of longest diameter of target lesions and for prostate cancer PR was defined as a ≥50% decrease in baseline prostate-specific antigen (PSA) value that was confirmed with a second value ≥3 weeks later. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase over nadir. SD was defined as small changes that did not meet above criteria.","timeFrame":"Baseline until progressive disease up to 36 weeks post-baseline"},{"measure":"Tumor Marker Values as Relevant to Specific Tumor Types at Baseline","description":"The number of participants with colorectal cancer (CRC), gastroesophageal cancer (GE), non-small cell lung cancer (NSCLC), ovarian cancer, prostate cancer or squamous cell carcinoma of head and neck (SCCHN) who had marker/molecular diagnostics performed prior to study entry to determine the mutation status of cancer genes: APC, BRAF, BRCA1, BRCA2, HRAS and KRAS and the presence of Human Papillovirus (HPV) and Epstein Barr viruses (EBV). Mutation/virus status was defined as: positive (mutation/virus present), negative (mutation/virus not present), unknown (mutation/virus status unknown), or not done (mutation/virus status was not done).","timeFrame":"Baseline"},{"measure":"Change in Tumor Size at Smallest Size (Best Response)","description":"The percent change in tumor size at its smallest size. The sum of diameters of target lesions was determined at each tumor assessment. The percent change is the smallest post-baseline sum divided by the baseline (pre-treatment) sum, multiplied by 100.","timeFrame":"Baseline until cycle with maximum change from baseline up to 36 weeks"},{"measure":"Pharmacokinetics, Maximum Plasma Concentration (Cmax) of LY2523355 and Metabolite LSN2546307","description":"Plasma Cmax following daily doses of LY2523355 on Days 1, 2, and 3 of Cycle 1 (21-day cycle).","timeFrame":"Day 3 of Cycle 1 (21-day cycle)"},{"measure":"Pharmacokinetics, Intracycle Accumulation Ratio (Ra) of LY2523355","description":"Intracycle Ra of LY2523355 is the ratio of LY2523355 maximum plasma concentration (Cmax) on Day 3 of Cycle 1 to the Cmax of LY2523355 on Day 1 of Cycle 1 following daily doses of LY2523355 on Days 1, 2 and 3 of Cycle 1 (21-day cycle) at each dose level.","timeFrame":"Day 1 and Day 3 of Cycle 1 (21-day cycle)"}],"otherOutcomes":[{"measure":"Number of Participants Who Died Due to Unknown Causes During the 30-Day Post-Study Treatment Follow-Up","timeFrame":"End of study treatment up to 30-days post-study treatment discontinuation"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of ovarian, non-small cell lung, prostate, colorectal, gastroesophageal cancer (adenocarcinoma of the esophageal cancer, stomach, or gastroesophageal junction), or squamous cell cancer of the head and neck\n* Have measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines (except prostate cancer participants)\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Are willing to follow study procedures for the duration of the study\n* Are willing to use an approved contraceptive method during treatment and for 3 months after discontinuation of study treatment\n\nExclusion Criteria:\n\n* Have a serious preexisting medical condition that would preclude participation in the study\n* Are pregnant or lactating\n* Have received treatment within 28 days of first dose of LY2523355 with a drug that has not received regulatory approval for any indication\n* Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases\n* Have a second active primary malignancy or a history of a second malignancy requiring cytotoxic therapy\n* Have QTc interval greater than 470 millisecond (msec) or intraventricular conduction delay (IVCD) with QRS greater than 120 msec on screening electrocardiogram (ECG)\n* Have active symptomatic fungal, bacterial, and/or known viral infection including active human immunodeficiency virus (HIV) or viral (A, B, C) hepatitis\n* Participants with pneumonia, evidence of obstructive pneumonitis, other respiratory infections, or infection from other sources are to be excluded","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1- 317-615-4559 Mon - Fri 9 AM to 5 PM (Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jonesboro","state":"Arkansas","zip":"72401","country":"United States","geoPoint":{"lat":35.8423,"lon":-90.70428}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Macon","state":"Georgia","zip":"31201","country":"United States","geoPoint":{"lat":32.84069,"lon":-83.6324}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Valdosta","state":"Georgia","zip":"31602","country":"United States","geoPoint":{"lat":30.83334,"lon":-83.28032}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Post Falls","state":"Idaho","zip":"83854","country":"United States","geoPoint":{"lat":47.71796,"lon":-116.95159}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Westwood","state":"Kansas","zip":"66205","country":"United States","geoPoint":{"lat":39.04056,"lon":-94.6169}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Baton Rouge","state":"Louisiana","zip":"70809","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bethesda","state":"Maryland","zip":"20817","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Billings","state":"Montana","zip":"59102","country":"United States","geoPoint":{"lat":45.78329,"lon":-108.50069}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Columbus","state":"Ohio","zip":"43219","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Oklahoma City","state":"Oklahoma","zip":"73120","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Memphis","state":"Tennessee","zip":"38120","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Corpus Christi","state":"Texas","zip":"78404","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Morgantown","state":"West Virginia","zip":"26506","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All participants who received at least one dose of study drug in both Cycle 1 and Cycle 2 or to have progressed or died on or before study Day 42 were considered to be completed.","groups":[{"id":"FG000","title":"LY2523355","description":"LY2523355: Dose determined by participant's body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21-day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"103"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"103"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"97"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All enrolled participants.","groups":[{"id":"BG000","title":"LY2523355","description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"103"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.3","spread":"10.30"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"33"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"70"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"101"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"8"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"93"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"103"}]}]}]},{"title":"Tumor Type","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Colorectal Cancer","categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}]},{"title":"Gastroesophageal Cancer","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]},{"title":"Non-Small Cell Lung Cancer","categories":[{"measurements":[{"groupId":"BG000","value":"29"}]}]},{"title":"Ovarian Cancer","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]},{"title":"Prostate Cancer","categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}]},{"title":"Squamous Cell Carcinoma of the Head and Neck","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Complete Response (CR) or Partial Response (PR)","description":"The percentage of participants who achieved a best response of either CR or PR, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm) and normalization of tumor marker level of non-target lesions. PR was defined as at least a 30% decrease in sum of longest diameter of target lesions and for prostate cancer PR was defined as a ≥50% decrease in baseline prostate-specific antigen (PSA) value that was confirmed with a second value ≥3 weeks later. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase over nadir. Percentage is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.","populationDescription":"All enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline until progressive disease up to 36 weeks post-baseline","groups":[{"id":"OG000","title":"LY2523355","description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Colorectal Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"17.1"}]}]},{"title":"Gastroesophageal Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"22.1"}]}]},{"title":"Non-Small Cell Lung Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Ovarian Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Prostate Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"16.2"}]}]},{"title":"Squamous Cell Carcinoma of Head and Neck","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"25.9"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS defined as the time from date of first dose to the first observation of disease progression or death due to any cause. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 millimeter (mm) increase over nadir. For participants who were not known to have died or to have progressed as of the data inclusion cutoff date, PFS were censored at the date of the last objective progression-free disease assessment prior to the date of any subsequent systemic anticancer therapy.","populationDescription":"All enrolled participants who received at least 1 dose of study drug. Percentage (%) of participants censored were colorectal cancer 5.9%; gastroesophageal cancer 0.0%, non-small cell lung cancer 3.4%, ovarian cancer 15.4%, prostate cancer 16.7%, and squamous cell carcinoma of the head and neck 15.4%.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"months","timeFrame":"Date of enrollment to progressive disease or death due to any cause up to 36 weeks post-enrollment","groups":[{"id":"OG000","title":"LY2523355","description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Colorectal Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","lowerLimit":"1.28","upperLimit":"2.69"}]}]},{"title":"Gastroesophageal Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","lowerLimit":"0.62","upperLimit":"1.51"}]}]},{"title":"Non-Small Cell Lung Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","lowerLimit":"1.28","upperLimit":"1.91"}]}]},{"title":"Ovarian Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","lowerLimit":"1.18","upperLimit":"2.10"}]}]},{"title":"Prostate Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","lowerLimit":"1.45","upperLimit":"2.66"}]}]},{"title":"Squamous Cell Carcinoma of Head and Neck","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.51","lowerLimit":"0.72","upperLimit":"2.76"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm) and normalization of tumor marker level of non-target lesions. PR was defined as at least a 30% decrease in sum of longest diameter of target lesions and for prostate cancer PR was defined as a ≥50% decrease in baseline prostate-specific antigen (PSA) value that was confirmed with a second value ≥3 weeks later. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase over nadir. SD was defined as small changes that did not meet above criteria.","populationDescription":"All enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline until progressive disease up to 36 weeks post-baseline","groups":[{"id":"OG000","title":"LY2523355","description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Colorectal Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","lowerLimit":"17.8","upperLimit":"60.9"}]}]},{"title":"Gastroesophageal Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","lowerLimit":"3.0","upperLimit":"43.8"}]}]},{"title":"Non-Small Cell Lung Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","lowerLimit":"22.6","upperLimit":"56.4"}]}]},{"title":"Ovarian Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"11.3","upperLimit":"57.3"}]}]},{"title":"Prostate Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","lowerLimit":"26.0","upperLimit":"68.9"}]}]},{"title":"Squamous Cell Carcinoma of Head and Neck","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"22.2","upperLimit":"77.8"}]}]}]},{"type":"SECONDARY","title":"Tumor Marker Values as Relevant to Specific Tumor Types at Baseline","description":"The number of participants with colorectal cancer (CRC), gastroesophageal cancer (GE), non-small cell lung cancer (NSCLC), ovarian cancer, prostate cancer or squamous cell carcinoma of head and neck (SCCHN) who had marker/molecular diagnostics performed prior to study entry to determine the mutation status of cancer genes: APC, BRAF, BRCA1, BRCA2, HRAS and KRAS and the presence of Human Papillovirus (HPV) and Epstein Barr viruses (EBV). Mutation/virus status was defined as: positive (mutation/virus present), negative (mutation/virus not present), unknown (mutation/virus status unknown), or not done (mutation/virus status was not done).","populationDescription":"All enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Baseline","groups":[{"id":"OG000","title":"LY2523355","description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"CRC-BRAF Mutation, Negative","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"CRC-BRAF Mutation, Not Done/Unknown","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]},{"title":"CRC-KRAS Mutation, Positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"CRC-KRAS Mutation, Negative","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"CRC-KRAS Mutation, Not Done","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"GE-KRAS Mutation, Negative","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"GE-KRAS Mutation, Not Done/Unknown","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]},{"title":"NSCLC-KRAS Mutation, Positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"NSCLC-KRAS Mutation, Negative","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"NSCLC-KRAS Mutation, Not Done/Unknown","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]},{"title":"Ovarian-BRCA1 Mutation, Negative","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Ovarian-BRCA1 Mutation, Not Done/Unknown","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Ovarian-BRCA2 Mutation, Negative","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Ovarian-BRCA2 Mutation, Not Done/Unknown","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"SCCHN-APC Mutation, Negative","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"SCCHN-APC Mutation, Not Done/Unknown","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]},{"title":"SCCHN-HPV (HPV-31 Positive) Mutation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"SCCHN-HPV Mutation, Not Done/Unknown","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]}]},{"type":"SECONDARY","title":"Change in Tumor Size at Smallest Size (Best Response)","description":"The percent change in tumor size at its smallest size. The sum of diameters of target lesions was determined at each tumor assessment. The percent change is the smallest post-baseline sum divided by the baseline (pre-treatment) sum, multiplied by 100.","populationDescription":"All enrolled participants who received at least 1 dose of study drug with results at baseline and at time of best response.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of change","timeFrame":"Baseline until cycle with maximum change from baseline up to 36 weeks","groups":[{"id":"OG000","title":"LY2523355","description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"}]}],"classes":[{"title":"Colorectal Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":"17.12"}]}]},{"title":"Gastroesophageal Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":"70.00"}]}]},{"title":"Non-Small Cell Lung Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":"48.69"}]}]},{"title":"Ovarian Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":"31.40"}]}]},{"title":"Prostate Cancer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"15.91"}]}]},{"title":"Squamous Cell Carcinoma of Head and Neck","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"30.67"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics, Maximum Plasma Concentration (Cmax) of LY2523355 and Metabolite LSN2546307","description":"Plasma Cmax following daily doses of LY2523355 on Days 1, 2, and 3 of Cycle 1 (21-day cycle).","populationDescription":"All enrolled participants who received at least 1 dose of study drug with Cmax measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanograms per milliliter (ng/mL)","timeFrame":"Day 3 of Cycle 1 (21-day cycle)","groups":[{"id":"OG000","title":"5 mg/m² LY2523355","description":"LY2523355: 5 milligrams/square meter/day (mg/m²/day) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 + pegfilgrastim on Day 4 of each 21-day cycle."},{"id":"OG001","title":"6 mg/m² LY253355","description":"LY2523355: 6 mg/m²/day administered intravenously as a one hour infusion on Days 1, 2, and 3 + pegfilgrastim on Day 4 of each 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"31"}]}],"classes":[{"title":"LY2523355","categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":"79"},{"groupId":"OG001","value":"124","spread":"67"}]}]},{"title":"LSN2546307","categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"51"},{"groupId":"OG001","value":"5.3","spread":"52"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics, Intracycle Accumulation Ratio (Ra) of LY2523355","description":"Intracycle Ra of LY2523355 is the ratio of LY2523355 maximum plasma concentration (Cmax) on Day 3 of Cycle 1 to the Cmax of LY2523355 on Day 1 of Cycle 1 following daily doses of LY2523355 on Days 1, 2 and 3 of Cycle 1 (21-day cycle) at each dose level.","populationDescription":"All enrolled participants who received at least 1 dose of study drug with Ra measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ratio","timeFrame":"Day 1 and Day 3 of Cycle 1 (21-day cycle)","groups":[{"id":"OG000","title":"5 mg/m²LY2523355","description":"LY2523355: 5 milligrams/square meter/day (mg/m²/day) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 + pegfilgrastim on Day 4 of each 21-day cycle."},{"id":"OG001","title":"6 mg/m² LY253355","description":"LY2523355: 6 mg/m²/day administered intravenously as a one hour infusion on Days 1, 2, and 3 + pegfilgrastim on Day 4 of each 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"87"},{"groupId":"OG001","value":"1.08","spread":"61"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Died Due to Unknown Causes During the 30-Day Post-Study Treatment Follow-Up","populationDescription":"All enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"End of study treatment up to 30-days post-study treatment discontinuation","groups":[{"id":"OG000","title":"LY2523355","description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"Deaths due to (d/t) PD not considered AEs and reported in Participant Flow for those who died during study treatment. Deaths d/t unknown cause in the 30-day post-study treatment follow-up (PSTF) reported in Other Pre-Specified Outcome Measure. One death (unknown cause) in PSTF recorded by investigator as an SAE included in SAE summary as \"Death\".","eventGroups":[{"id":"EG000","title":"LY2523355","description":"LY2523355: Dose determined by participant's body surface area: 5 milligrams/meter squared (mg/m²) or 6 mg/m², administered intravenously on days 1, 2, 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously 24 hours after third dose of LY2523355 on day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment.","seriousNumAffected":39,"seriousNumAtRisk":103,"otherNumAffected":102,"otherNumAtRisk":103}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":103}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":103}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":103}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Enterovesical fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":103}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":103}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":103}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":103}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":103}]},{"term":"Rectal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"1 event resulted in death","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":103}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":103}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":103}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":103}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":103}]},{"term":"Malignant ascites","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Event resulted in death","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":103}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"1 event resulted in death","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":103}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":103}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":33,"numAtRisk":103}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":21,"numAtRisk":103}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":13,"numAtRisk":103}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":103}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":24,"numAtRisk":103}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":18,"numAtRisk":103}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":103}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":35,"numAtRisk":103}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":103}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":103}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":103}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":103}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":54,"numAffected":45,"numAtRisk":103}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":19,"numAtRisk":103}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":103}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":103}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":103}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":103}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":103}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":103}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":103}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":26,"numAtRisk":103}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":103}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":103}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":103}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":103}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":103}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":103}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":103}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":103}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":103}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":103}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":103}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":103}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":103}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":15,"numAtRisk":103}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":103}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":103}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D010051","term":"Ovarian Neoplasms"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D011471","term":"Prostatic Neoplasms"},{"id":"D015179","term":"Colorectal Neoplasms"},{"id":"D013274","term":"Stomach Neoplasms"},{"id":"D004938","term":"Esophageal Neoplasms"},{"id":"D006258","term":"Head and Neck Neoplasms"}],"ancestors":[{"id":"D004701","term":"Endocrine Gland Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D010049","term":"Ovarian Diseases"},{"id":"D000291","term":"Adnexal Diseases"},{"id":"D005831","term":"Genital Diseases, Female"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D005833","term":"Genital Neoplasms, Female"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D006058","term":"Gonadal Disorders"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D005834","term":"Genital Neoplasms, Male"},{"id":"D005832","term":"Genital Diseases, Male"},{"id":"D011469","term":"Prostatic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D007414","term":"Intestinal Neoplasms"},{"id":"D005770","term":"Gastrointestinal Neoplasms"},{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D003108","term":"Colonic Diseases"},{"id":"D007410","term":"Intestinal Diseases"},{"id":"D012002","term":"Rectal Diseases"},{"id":"D013272","term":"Stomach Diseases"},{"id":"D004935","term":"Esophageal Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000591843","term":"litronesib"},{"id":"C455861","term":"pegfilgrastim"}]}},"hasResults":true}